Related references
Note: Only part of the references are listed.Highly Stabilized Curcumin Nanoparticles Tested in an In Vitro Blood-Brain Barrier Model and in Alzheimer's Disease Tg2576 Mice
Kwok Kin Cheng et al.
AAPS JOURNAL (2013)
The global prevalence of dementia: A systematic review and metaanalysis
Martin Prince et al.
ALZHEIMERS & DEMENTIA (2013)
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
John M. Ringman et al.
ALZHEIMERS RESEARCH & THERAPY (2012)
Innovative Preparation of Curcumin for Improved Oral Bioavailability
Hiroki Sasaki et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2011)
Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
Todd E. Golde et al.
NEURON (2011)
Curcuminoids Rescue Long-Term Potentiation Impaired by Amyloid Peptide in Rat Hippocampal Slices
Touqeer Ahmed et al.
SYNAPSE (2011)
Amyloid-beta Production Via Cleavage of Amyloid-beta Protein Precursor is Modulated by Cell Density
Can Zhang et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Phenolic Compounds Prevent Alzheimer's Pathology through Different Effects on the Amyloid-β Aggregation Pathway
Tsuyoshi Hamaguchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer
J. Shaikh et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Accumulated Amyloid-beta Peptide and Hyperphosphorylated Tau Protein: Relationship and Links in Alzheimer's Disease
Han-Chang Huang et al.
JOURNAL OF ALZHEIMERS DISEASE (2009)
Curcumin protected PC12 cells against beta-amyloid-induced toxicity through the inhibition of oxidative damage and tau hyperphosphorylation
So-Young Park et al.
FOOD AND CHEMICAL TOXICOLOGY (2008)
Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease
Larry Baum et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2008)
Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease
Aynun N. Begum et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Epigallocatechin-3-gallate and curcumin suppress amyloid beta-induced beta-site APP cleaving enzyme-1 upregulation
Yoshiari Shimmyo et al.
NEUROREPORT (2008)
Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: Blockage by curcumin
Raozhou Lin et al.
NEUROSCIENCE LETTERS (2008)
High-performance liquid chromatography analysis of curcumin in rat plasma: application to pharmacokinetics of polymeric micellar formulation of curcumin
Zengshuan Ma et al.
BIOMEDICAL CHROMATOGRAPHY (2007)
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Monica Garcia-Alloza et al.
NEUROBIOLOGY OF DISEASE (2006)
Curry consumption and cognitive function in the elderly
Tze-Pin Ng et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Mild cognitive impairment: An opportunity to identify patients at high risk for progression to Alzheimer's disease
Allan Levey et al.
CLINICAL THERAPEUTICS (2006)
Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin
AC Liu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2006)
Effects of naturally occurring compounds on fibril formation and oxidative stress of β-amyloid
H Kim et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2005)
Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo
FS Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro
K Ono et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2004)
Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
SA Frautschy et al.
NEUROBIOLOGY OF AGING (2001)
Apolipoprotein E polymorphism and Alzheimer disease -: The Indo-US cross-national dementia study
M Ganguli et al.
ARCHIVES OF NEUROLOGY (2000)
Identification of the major Aβ1-42-degrading catabolic pathway in brain parenchyma:: Suppression leads to biochemical and pathological deposition
N Iwata et al.
NATURE MEDICINE (2000)
Share Paper
